syntro.ai

What It Is

Syntro is an AI platform built for pharmaceutical companies and CRO teams, positioned around automated regulatory and medical writing, with a particular focus on literature review for pharmacovigilance. Users can enter a research question, such as whether a given drug is associated with a specific adverse event, and the system generates keywords and search queries, then analyzes, labels, and filters the retrieved literature.

Core Capabilities

Based on the information on the page, Syntro is not focused on general-purpose chat. Instead, it is built around workflows for drug safety and medical evidence retrieval. It can suggest keywords such as drugs, diseases, dosages, adverse reactions, and related terms based on a research question, then generate queries similar to PubMed search syntax. It subsequently performs contextual analysis on paper abstracts, extracts labels such as adult, drug, adverse reaction, overdose, and disease, and answers user questions. Its intelligent filtering is designed to prioritize high-value evidence, remove noise, and categorize results by topic, making it suitable for scenarios such as PSUR, ICSR, clinical documentation, and medical affairs Q&A.

Pricing and Trial

The page provides entry points for Book a demo, Schedule a meeting, and Try it out, but does not disclose any free quota, trial period, package pricing, or enterprise licensing model. Before procurement, buyers will need to confirm pricing, number of accounts, literature volume limits, compliance terms, and support arrangements with the vendor.

Pros and Cons

The main advantage is its vertical focus: it closely matches the literature screening workflow used in pharmacovigilance. It can convert natural-language questions into structured search strategies, reducing the search burden for medical writers. Its outputs include PMID, DOI, abstracts, and tags, offering a degree of traceability. The limitations are that public materials do not explain the underlying model, database coverage, validation metrics, data privacy policy, or API integration capabilities. The examples also show that when dosage information is not present in an abstract, the system can only state that it is unspecified; it cannot replace human medical judgment.

Who It’s For and Access from China

Syntro is best suited to pharmaceutical pharmacovigilance teams, CROs, medical writing teams, and medical affairs teams that want to improve the efficiency of initial literature screening and evidence organization. Access from mainland China is not addressed in the available text, and network availability, payment methods, and contracting processes are all unknown. If access is limited, alternatives such as PubMed, Embase, Rayyan, Covidence, DistillerSR, or Elicit may be considered, but compliance and suitability for pharmacovigilance workflows should be evaluated separately.